Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
gene editing
3
×
life sciences
national blog main
boulder/denver blog main
boulder/denver top stories
crispr
detroit blog main
detroit top stories
editas medicine
eli lilly
katrine bosley
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vertex pharmaceuticals
wisconsin blog main
wisconsin top stories
abbvie
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
allergan
allergan aesthetics
alzheimer's disease
amgen
What
ceo
3
×
bio
crispr
editas
katrine
medicine
moves
roundup
week
acquisitions
allergan
big
biggest
blessing
bosley
bosley's
bosley’s
bridge
bucks
build
buy
cas
check
clinical
company’s
crime
cusp
daniel
debut
depart
departure
drug
dyne’s
editing
exit
experimental
gene
gilead
guiding
humans
Language
unset
Current search:
ceo
×
biotech
×
" gene editing "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial